AMPLYX PHARMACEUTICALS
Amplyx Pharmaceuticals is a pre-clinical stage company focusing on the development of small molecule drugs with enhanced efficacy and lower toxicity. Amplyx employs a platform approach to improve small molecule drugs by the addition of a second small molecule to an existing drug. The company develops innovative therapies for debilitating and life-threatening diseases that affect people with compromised immune systems. Amplyx Pharmaceuticals was founded in 2006 and is headquartered in San Diego, California.
AMPLYX PHARMACEUTICALS
Industry:
Biotechnology Clinical Trials Medical Pharmaceutical
Founded:
2006-01-01
Address:
San Diego, California, United States
Country:
United States
Website Url:
http://www.amplyx.com
Total Employee:
11+
Status:
Active
Contact:
+118583484458
Total Funding:
198.37 M USD
Technology used in webpage:
SPF Microsoft Exchange Online Office 365 Mail Microsoft Azure DNS Oracle Cloud Proofpoint
Similar Organizations
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
Apellis Pharmaceuticals
Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
PaxVax
PaxVax is a start-up developing candidate oral vaccines for key infectious diseases.
PhaseBio Pharmaceuticals
PhaseBio is a clinical-stage biopharmaceutical company that develops drugs for cardiovascular diseases, endocrine, and metabolic disorders.
Recro Pharma
Recro Pharma is a pharmaceutical company developing non-opioid therapeutics for the treatment of pain.
ZS Pharma
ZS Pharma develops ion trap therapies for the treatment of life-threatening medical conditions such as hyperkalemia and liver diseases.
Current Advisors List
Board_member
Board_member
Board_member
Board_member
Board_member
2017-08-01
Board_member
Board_member
2016-01-01
Current Employees Featured
Mike Grey President & CEO @ Amplyx Pharmaceuticals
President & CEO
2015-10-01
Christopher LeMasters COO @ Amplyx Pharmaceuticals
COO
Kevin Holme Senior Vice President of Development @ Amplyx Pharmaceuticals
Senior Vice President of Development
Elaine J. Heron Director @ Amplyx Pharmaceuticals
Director
2009-02-01
Paul Bien VP of Program Management & Operations @ Amplyx Pharmaceuticals
VP of Program Management & Operations
Carlos Sattler SVP of Clinical Development @ Amplyx Pharmaceuticals
SVP of Clinical Development
Pamela Wedel VP of Clinical Operations @ Amplyx Pharmaceuticals
VP of Clinical Operations
Founder
Investors List
Pappas Capital
Pappas Capital investment in Series C - Amplyx Pharmaceuticals
Adage Capital Management
Adage Capital Management investment in Series C - Amplyx Pharmaceuticals
Arix Bioscience
Arix Bioscience investment in Series C - Amplyx Pharmaceuticals
Pfizer
Pfizer investment in Series C - Amplyx Pharmaceuticals
BioMed Ventures
BioMed Ventures investment in Series C - Amplyx Pharmaceuticals
RiverVest
RiverVest investment in Series C - Amplyx Pharmaceuticals
Lundbeckfonden Ventures
Lundbeckfonden Ventures investment in Series C - Amplyx Pharmaceuticals
New Enterprise Associates
New Enterprise Associates investment in Series C - Amplyx Pharmaceuticals
3×5 Partners
3×5 Partners investment in Series C - Amplyx Pharmaceuticals
Sofinnova Investments
Sofinnova Investments investment in Series C - Amplyx Pharmaceuticals
Key Employee Changes
| Date | New article |
|---|---|
| 2020-06-08 | Amplyx Pharmaceuticals Expands Executive Leadership Team |
| 2020-02-04 | Amylyx Pharmaceuticals Appoints Jeffrey Trigilio Chief Financial Officer |
Official Site Inspections
http://www.amplyx.com
- Host name: 147.154.27.36
- IP address: 147.154.27.36
- Location: Seattle United States
- Latitude: 47.6109
- Longitude: -122.3303
- Metro Code: 819
- Timezone: America/Los_Angeles
- Postal: 98101
More informations about "Amplyx Pharmaceuticals"
Our Company - Amylyx
Our co-CEOs Josh Cohen and Justin Klee founded Amylyx in 2013 and have continued to build an organization on an audacious pursuit to discover and develop novel therapies for high …See details»
Careers - Amylyx
Amylyx team members created snack kits that will help families in the Greater Boston area in partnership with a local organization. Our mission is powered by our people We know …See details»
Amylyx Pharmaceuticals - Crunchbase Company Profile …
Organization. Amylyx Pharmaceuticals . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. About. ... Amylyx Pharmaceuticals reported robust revenue growth and net income for …See details»
Amylyx Pharmaceuticals - Wikipedia
Amylyx Pharmaceuticals was founded in 2013 by Joshua Cohen and Justin Klee when the two were undergraduate students at Brown University. The two proposed that taurursodiol and sodium phenylbutyrate together might prevent dysfunction of mitochondria and the endoplasmic reticulum, safeguarding neurons. Klee and Cohen were advised by Rudolph E. Tanzi, who ultimately served as the founding chair of Amylyx's scientific research board. After Klee and Cohen were able to a…See details»
‘1 plus 1 equals 3’ — the co-CEO model in pharma - PharmaVoice
Jan 26, 2024 Amylyx Pharmaceuticals’ co-founders and co-CEOs Josh Cohen and Justin Klee explain their approach to dual leadership and why it can be a good fit in life sciences. ... For …See details»
Amylyx - The Org
Amylyx Pharmaceuticals specializes in providing solutions for Alzheimer’s and other diseases of the brain. Industries. Biotechnology, Health Care +2. Headquarters. Cambridge, United States. …See details»
Amylyx Pharmaceuticals, Inc. (AMLX) - Yahoo Finance Canada
Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts. Corporate Governance . Amylyx Pharmaceuticals, Inc.’s ISS Governance …See details»
Amylyx Company Profile - Office Locations, Competitors, Revenue …
Oct 29, 2024 Amylyx has 3 employees across 8 locations and $380.79 m in annual revenue in FY 2023. See insights on Amylyx including office locations, competitors, revenue, financials, …See details»
Amylyx Pharmaceuticals - Funding, Financials, Valuation & Investors
Amylyx Pharmaceuticals is registered under the ticker NASDAQ:AMLX . Their stock opened with $19.00 in its Jan 7, 2022 IPO. Amylyx Pharmaceuticals is funded by 20 investors. 683 …See details»
Amylyx Pharmaceuticals - Contacts, Employees, Board Members, …
Organization. Amylyx Pharmaceuticals . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. ... Contacts 217. About. Amylyx Pharmaceuticals has 6 current …See details»
Amylyx Pharmaceuticals - Overview, News & Similar companies
May 9, 2024 Who is Amylyx Pharmaceuticals. Amylyx Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company developing a novel therapeutic for Amyotrophic Lateral Sclerosis …See details»
Amylyx Pharmaceuticals Appoints Dan Monahan as Chief …
5 days ago CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced the appointment of Dan Monahan as …See details»
Amylyx Pharmaceuticals Announces Pricing of Public Offering of …
1 day ago CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 10, 2025-- Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced the pricing of an …See details»
Amylyx Pharmaceuticals, Inc.
Tabl e of Conte nts As confidentially submitted to the Securities and Exchange Commission on November 24, 2021. This Amendment No. 2 to the draft registration statement has not beSee details»
Amylyx Pharmaceuticals Announces Proposed Public Offering of …
1 day ago In addition, Amylyx intends to grant the underwriter a 30-day option to purchase additional shares of its common stock in an amount up to 15% of the shares offered in the …See details»
Hear stories from the ALS community | Together for ALS
Together for ALS began as a way to share the experiences of people living with ALS and their loved ones. Supported by patient advocacy groups across Europe, including Stichting ALS in …See details»
Amylyx Pharmaceuticals Prices Offering Of Approx. 17.1 Mln
1 day ago (RTTNews) - Amylyx Pharmaceuticals, Inc. (AMLX), a Massachusetts-based biopharmaceutical company, Friday announced the pricing of an underwritten public offering of …See details»
Amylyx Pharmaceuticals to Report Second Quarter 2024 Financial …
Aug 5, 2024 Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) will report its second quarter 2024 financial results on Thursday, August 8, 2024. Amylyx’ senior …See details»
Amylyx Pharma Commences Underwritten Public Offering Of Shares
1 day ago In addition, Amylyx intends to grant the underwriter a 30-day option to purchase additional shares of its common stock in an amount up to 15% of the shares offered in the …See details»
Amylyx Pharmaceuticals Reports Third Quarter 2024 Financial Results
Sep 30, 2024 CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today reported financial results for the third …See details»